Skip to main content
New Therapeutic Options: Management Strategies to Optimize Glycemic Control
Journal of the American Osteopathic Association
  • Jeffrey S. Freeman, Philadelphia College of Osteopathic Medicine
Document Type
Publication Date
Management of type 2 diabetes mellitus (T2DM) can be challenging. Patients frequently present with poor glycemic control despite therapy. Other patients may be nonadherent or resistant to continuing their treatment when confronted with undesirable adverse effects, such as weight gain, that are associated with many conventional therapies. Incretin-based therapies developed to treat patients with T2DM, including oral dipeptidyl peptidase-4 inhibitor agents or glucagon-like peptide-1 agonists, offer the potential of sustained glycemic control for many patients without the adverse events associated with other classes of antihyperglycemic medications. Available safety data from clinical trials indicate that incretin-based therapies have weight-neutral or weight-reducing effects, with no apparent adverse impact on other important safety parameters, such as cardiovascular disease. The integration of these therapies into treatment algorithms, as highlighted in three case presentations, will increase treatment options for patients with T2DM.
PubMed ID

This article was published in Journal of the American Osteopathic Association, Volume 110, Issue 3 Supplement 2, March 2010, Pages S15-20.

The published version is available at

Copyright © 2010 by the American Osteopathic Association

Citation Information
Jeffrey S. Freeman. "New Therapeutic Options: Management Strategies to Optimize Glycemic Control" Journal of the American Osteopathic Association Vol. 110 Iss. 3 Suppl 2 (2010) p. S15 - S20
Available at: